TheTechno Optimist.

Sacituzumab tirumotecan (sac-TMT)Merck & Co.—Merck's sac-TMT improves survival in TroFuse-005, its first positive global phase 3, in endometrial cancerSacituzumab tirumotecan (sac-TMT)Merck & Co.—Sac-TMT plus Keytruda cuts lung cancer progression risk by 65% versus Keytruda alone in a China trial

Merck & Co.

Keytruda, sac-TMT antibody-drug conjugate, oncology

USpublicmerck.com (opens merck.com)Checked 11 Oct

The brief

Analyst view
  • Sac-TMT: 17 global phase 3 trials enrolling 15,000+ patients, 10 of them in women's cancers.
  • First global phase 3 win (TroFuse-005, endometrial cancer) in May 2026, on both survival and progression.
  • Licensed outside Greater China from Kelun-Biotech in May 2022.
Primer